'Same price at every dose'
ConfirmedThe plans page shows $139 per month on a 12-month supply down to $149 on monthly auto-refill for the selected drug, against a struck-through $339. We confirmed this ourselves.
Where the vendor states thisTelehealth GLP-1 prescriptions
A direct-to-consumer telehealth brand offering compounded semaglutide and tirzepatide, microdosed GLP-1, and a longevity catalog that includes sermorelin, NAD+ in several forms, MIC+B12, glutathione and methylene blue.
We may earn a commission if you buy through the links to Lttl on this page, at no extra cost to you. That does not change how we grade or rank it, and Lttl did not write or approve this review.

quality claims we could confirm ourselves, rather than repeat from the vendor's marketing.
Compounded semaglutide and tirzepatide, sermorelin, NAD+ injectable, nasal and oral, MIC+B12, L-carnitine, glutathione and methylene blue.
Everything here is a prescription service that starts with a licensed clinician's review of your own health information. Compounded medications are made by a pharmacy against a prescription and are not FDA-approved or reviewed by the FDA for safety, effectiveness or quality. This entry describes what the brand offers and what we could check. It is not medical advice and not a recommendation to use it.
Every telehealth brand we rank gets the same five checks, read from its public pages on September 24, 2026. "Not met" means we did not find it, or the terms say otherwise, on the pages we could read. Price and commission play no part.
The plans page prints a price for each commitment length, from $139 to $149 a month.
Names clinicians including Dr. Stan Saji, PharmD and Corinne Curran, FNP-C.
Says it partners with certified U.S. pharmacies but names none.
Says 'cancel anytime'. We could not read a published refund policy.
No warning letter under this name in FDA's public database on September 24, 2026.
Graded by whether we could confirm it ourselves or are only repeating what the vendor states. A vendor's honesty about its own testing is a different question from what a published trial shows, so this is a separate scale from the evidence grades on our guides.
The plans page shows $139 per month on a 12-month supply down to $149 on monthly auto-refill for the selected drug, against a struck-through $339. We confirmed this ourselves.
Where the vendor states thisBoth are the brand's own statements on its pages. We could not find who rated it or the basis for the award, so we treat them as marketing until a source is shown.
Where the vendor states thisStated in the banner. Turnaround depends on clinician review, so we did not test it. We confirmed this ourselves.
Where the vendor states thisFDA does not review compounded drugs for safety, effectiveness or quality before they are sold. In 2026 FDA warned 30 telehealth companies over claims implying sameness with approved drugs, and proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, so the legal footing of this category can change.
Showing a crossed-out $339 next to $139 to $149 makes the discount look larger. What matters is the price you actually pay each month.
'#1 rated for results' and the Forbes Health line are not linked to a study or a ranking we could open.
That is what the brand says. The plans page shows one price per plan length, but we did not test dose changes.
Every fact above traces to one of these pages, published by the vendor itself and checked on September 25, 2026. Vendor policy pages change without notice, so if something here looks out of date, it probably is.
Compare against
Open pricing, public COAs, strict research-only gate